- Home
- ACCS vs BLRX Comparison
ACCS vs BLRX Comparison
Compare ACCS & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACCS | BLRX |
|---|---|---|
| Founded | 1988 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Publishing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6M | 11.7M |
| IPO Year | 2014 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ACCS | BLRX |
|---|---|---|
| Price | $3.61 | $1.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | $9.50 | ★ $22.00 |
| AVG Volume (30 Days) | ★ 14.0K | 9.4K |
| Earning Date | 11-10-2026 | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 139.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,619,000.00 | N/A |
| Revenue This Year | N/A | $37.33 |
| Revenue Next Year | $3.21 | $37.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.21 | $1.40 |
| 52 Week High | $11.34 | $3.95 |
Technical Indicators
Market Signals| Indicator | ACCS | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.49 | 13.73 |
| Support Level | $3.21 | N/A |
| Resistance Level | $5.11 | $3.04 |
| Average True Range (ATR) | 0.33 | 0.13 |
| MACD | 0.02 | -0.05 |
| Stochastic Oscillator | 37.11 | 0.00 |
Price Performance
Historical ComparisonAbout ACCS ACCESS Newswire Inc.
ACCESS Newswire Inc is a Public Relations (PR) and Investor Relations (IR) solutions provider. The group focuses on innovation, customer service, and value-driven offerings, ACCESS Newswire empowers brands.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.